The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
An expert roundtable of headache specialists helps outline chronic migraine as its own entity, disparities and barriers to treatment, and a need for better research and education.
Trudhesa uses proprietary technology to deliver a lower dose (0.725mg per spray) of dihydroergotamine mesylate to the upper nasal space.
Patients treated with gammaCore experienced clinically meaningful benefits.
The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.
The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.
Nerivio is a wireless remote electrical neuromodulation device approved for the acute treatment of episodic or chronic migraine in patients 12 years of age and older.
Researchers searched publication databases for studies of the gut-brain connection, migraine, and gastric disorders.
Rimegepant is an oral calcitonin gene-related peptide receptor antagonist.
Atorvastatin may have augmentative effects with sodium valproate in the reduction of migraines with aura.
